MA52415A - Dérivés de triazine pour le traitement de maladies associées à des neurotrophines - Google Patents
Dérivés de triazine pour le traitement de maladies associées à des neurotrophinesInfo
- Publication number
- MA52415A MA52415A MA052415A MA52415A MA52415A MA 52415 A MA52415 A MA 52415A MA 052415 A MA052415 A MA 052415A MA 52415 A MA52415 A MA 52415A MA 52415 A MA52415 A MA 52415A
- Authority
- MA
- Morocco
- Prior art keywords
- neurotrophins
- treatment
- diseases associated
- triazine derivatives
- triazine
- Prior art date
Links
- 108010025020 Nerve Growth Factor Proteins 0.000 title 1
- 102000007072 Nerve Growth Factors Human genes 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 150000003918 triazines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/30—Only oxygen atoms
- C07D251/34—Cyanuric or isocyanuric esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/30—Only oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1850217 | 2018-02-26 | ||
| GBGB1810667.4A GB201810667D0 (en) | 2018-06-28 | 2018-06-28 | New compounds and uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52415A true MA52415A (fr) | 2021-01-06 |
Family
ID=65729389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052415A MA52415A (fr) | 2018-02-26 | 2019-02-26 | Dérivés de triazine pour le traitement de maladies associées à des neurotrophines |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US11352332B2 (fr) |
| EP (1) | EP3759088B8 (fr) |
| JP (1) | JP7350759B2 (fr) |
| KR (1) | KR20200126988A (fr) |
| CN (1) | CN111819172B (fr) |
| AU (1) | AU2019223333A1 (fr) |
| BR (1) | BR112020017341A2 (fr) |
| CA (1) | CA3090864A1 (fr) |
| CL (1) | CL2020002157A1 (fr) |
| DK (1) | DK3759088T3 (fr) |
| ES (1) | ES2941529T3 (fr) |
| FI (1) | FI3759088T3 (fr) |
| HR (1) | HRP20230290T1 (fr) |
| HU (1) | HUE061751T2 (fr) |
| IL (1) | IL276624B2 (fr) |
| LT (1) | LT3759088T (fr) |
| MA (1) | MA52415A (fr) |
| MX (1) | MX2020008816A (fr) |
| PL (1) | PL3759088T3 (fr) |
| PT (1) | PT3759088T (fr) |
| SG (1) | SG11202007136VA (fr) |
| SI (1) | SI3759088T1 (fr) |
| WO (1) | WO2019162702A1 (fr) |
| ZA (1) | ZA202004220B (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201810668D0 (en) | 2018-06-28 | 2018-08-15 | Stiftelsen Alzecure | New compounds |
| GB201912404D0 (en) * | 2019-08-29 | 2019-10-16 | AlzeCure Pharma AB | New compounds |
| BR112022026400A2 (pt) * | 2020-06-23 | 2023-01-17 | Shenyang Sinochem Agrochemicals R & D Co Ltd | Composto de benzoato de triazina e aplicação do mesmo |
| CN113831299B (zh) * | 2020-06-23 | 2023-12-01 | 沈阳中化农药化工研发有限公司 | 苯甲酸酯类化合物及其应用 |
| CN113831298B (zh) * | 2020-06-23 | 2023-12-01 | 沈阳中化农药化工研发有限公司 | 光活性羧酸酯类化合物及其应用 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2246109A1 (de) * | 1972-09-20 | 1974-03-28 | Bayer Ag | 1-(4-phenoxy-phenyl)-1,3,5-triazinderivate, ein verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel |
| DE2313721A1 (de) | 1973-03-20 | 1974-10-03 | Bayer Ag | Neue 1-phenylsubstituierte 1,3,5triazine, verfahren zu ihrer herstellung, sowie ihre verwendung als arzneimittel |
| DE2413722C3 (de) * | 1974-03-21 | 1982-04-08 | Bayer Ag, 5090 Leverkusen | Neue 1-(4-Phenoxy-phenyl)-1,3,5-triazin-Derivate, ein Verfahren zu ihrer Herstellung sowie ihre Anwendung als Arzneimittel |
| DE2718799A1 (de) | 1977-04-27 | 1978-11-09 | Bayer Ag | 1-(4-phenoxy-phenyl)-1,3,5-triazin- derivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel und wachstumsfoerderer |
| CA1185974A (fr) | 1981-12-03 | 1985-04-23 | Adolf Parg | 1,3,5-triazinones et utilisation pour empecher la croissance des mauvaises herbes |
| DE3314739A1 (de) | 1983-04-23 | 1984-10-25 | Bayer Ag, 5090 Leverkusen | 1-(4-(4-(fluoralkylmethylthio- oder -sulfinyl- oder -sulfonyl-)phenoxy) phenyl)-1,3,5-triazin-2,4,6(1h,3h,5h)-trione, verfahren zu ihrer herstellung und ihre verwendung als coccidiosemittel |
| DE3408768A1 (de) | 1984-03-09 | 1985-09-12 | Bayer Ag, 5090 Leverkusen | Immunstimulierende mittel |
| DE3516632A1 (de) | 1985-05-09 | 1986-11-13 | Bayer Ag, 5090 Leverkusen | Verfahren zur herstellung von 1,3,5-triazintrionen |
| DE3516631A1 (de) | 1985-05-09 | 1986-11-13 | Bayer Ag, 5090 Leverkusen | Verfahren zur herstellung von 3-methyl-1,3,5-triazintrionen |
| DE3703105A1 (de) * | 1987-02-03 | 1988-08-11 | Bayer Ag | Mittel gegen protozoen bei insekten |
| DE3810080A1 (de) | 1988-03-25 | 1989-10-05 | Bayer Ag | Trisubstituierte 1,3,5-triazin-2,4,6-trione |
| DE3814323A1 (de) | 1988-04-28 | 1989-11-09 | Hoechst Ag | Wasserloesliche zubereitungen von coccidiostatica |
| US4933341A (en) | 1988-10-08 | 1990-06-12 | Bayer Aktiengesellschaft | Substituted 1,3,5-triazinetriones, for use against parasitic protozoa |
| DE4000624A1 (de) | 1990-01-11 | 1991-07-18 | Bayer Ag | Fungizide verwendung von trisubstituierten 1,3,5-triazin-2,4,6-trionen, neue trisubstituierte 1,3,5-triazin-2,4,6-trione und verfahren zu ihrer herstellung |
| DE4329096A1 (de) | 1993-08-30 | 1995-03-02 | Bayer Ag | Heterocyclylbenzoheterocyclen |
| US5604180A (en) | 1995-06-02 | 1997-02-18 | Crews, Jr.; Alvin D. | 3-(3-aryloxyphenyl)-1 (substituted methyl)-s-triazine-2,4,6-oxo or thiotrione herbicidal agents |
| US5726126A (en) | 1995-06-02 | 1998-03-10 | American Cyanamid Company | 1-(3-heterocyclyphenyl)-S-triazine-2,6,6-oxo or thiotrione herbicidal agents |
| US5519133A (en) | 1995-06-02 | 1996-05-21 | American Cyanamid Co. | 3-(3-aryloxyphenyl)-1-(substituted methyl)-s-triazine-2,4,6-oxo or thiotrione herbicidal agents |
| CZ146296A3 (en) | 1995-06-02 | 1997-04-16 | American Cyanamid Co | 3-(3-aryloxyphenyl)-1-(substituted methyl)-s-triazine-2,4,6-oxo or thiotriones, process of their preparation and herbicidal agents |
| US5679791A (en) | 1996-07-25 | 1997-10-21 | American Cyanamid Company | 1-(3-heterocyclylphenyl)-s-triazine-2,4,6-oxo or thiotrione herbicidal agents |
| CA2346463A1 (fr) | 1998-10-08 | 2000-04-13 | New Ace Research Company | Nouvelles compositions et nouveaux procedes destines a la prevention et au traitement de maladies provoquees par des protozoaires |
| AU2198100A (en) | 1998-12-22 | 2000-07-12 | Bayer Corporation | Triazineone compounds for treating diseases due to sarcosystis, neospora and toxoplasma |
| DE19937500A1 (de) | 1999-08-09 | 2001-02-15 | Bayer Ag | Substituierte Heterocyclylbenzofurane |
| DE19958388A1 (de) | 1999-12-03 | 2001-06-07 | Bayer Ag | Triazinonverbindungen zur Behandlung von durch den Befall mit parasitischen Protozoen bedingten Krankheiten |
| US6444615B1 (en) | 2000-04-18 | 2002-09-03 | Dow Agrosciences Llc | Herbicidal imidazolidinetrione and thioxo-imidazolidinediones |
| DE10034800A1 (de) | 2000-07-18 | 2002-01-31 | Bayer Ag | Substituierte Benzostickstoffheterocyclen |
| DE10040174A1 (de) | 2000-08-17 | 2002-02-28 | Bayer Ag | Verwendung von Triazintrion-Sulfonen zur Bekämpfung von Coccidiosen |
| DE10040110A1 (de) | 2000-08-17 | 2002-02-28 | Bayer Ag | Verwendung von Triazintrion-Sulfoxiden zur Bekämpfung von Coccidiosen |
| AU2002324586B2 (en) | 2001-08-02 | 2008-04-24 | Neurocrine Biosciences, Inc. | 1,3,5-triazine-2,4,6-triones, preparation and use as gonadotropin-releasing hormone receptor antagonists |
| JPWO2003029199A1 (ja) | 2001-09-28 | 2005-01-13 | 武田薬品工業株式会社 | ベンゼン誘導体、その製造法および用途 |
| US6861523B2 (en) | 2002-02-08 | 2005-03-01 | Torrey Pines Institute For Molecular Studies | 1,3,5- trisubstituted-1,3,5-triazine-2,4,6-trione compounds and libraries |
| EP1523485B1 (fr) | 2002-07-15 | 2007-02-14 | Janssen Pharmaceutica N.V. | Analogues de 3-furanyle de toxoflavine en tant qu'inhibiteurs de kinase |
| DE102006038292A1 (de) | 2006-08-16 | 2008-02-21 | Bayer Healthcare Ag | Transdermale Anwendung von Triazinen zur Bekämpfung von Coccidien-Infektionen |
| WO2008148008A1 (fr) | 2007-05-23 | 2008-12-04 | Emory University | Dosage biologique a haut rendement servant a identifier des agonistes selectifs du recepteur trka, ainsi que l'amide gambogique, un agoniste selectif de trka presentant une activite neuroprotectrice |
| EP3097090B1 (fr) | 2014-01-20 | 2018-10-10 | F. Hoffmann-La Roche AG | Dérivés de n-phényl-lactame aptes à stimuler la neurogenèse et leur utilisation dans le traitement des désordres neurologiques |
| WO2016094690A1 (fr) | 2014-12-10 | 2016-06-16 | Mars, Incorporated | Compositions aromatisantes et produits alimentaires pour animaux de compagnie les contenant |
| AU2017380583A1 (en) | 2016-12-21 | 2019-06-27 | AlzeCure Pharma AB | Triazinetrione derivatives and their use as modulators of neurotrophin receptor and receptor tyrosine kinases |
| GB201810668D0 (en) | 2018-06-28 | 2018-08-15 | Stiftelsen Alzecure | New compounds |
| GB201810669D0 (en) | 2018-06-28 | 2018-08-15 | Stiftelsen Alzecure | New compounds |
-
2019
- 2019-02-26 HU HUE19710473A patent/HUE061751T2/hu unknown
- 2019-02-26 PL PL19710473.0T patent/PL3759088T3/pl unknown
- 2019-02-26 MA MA052415A patent/MA52415A/fr unknown
- 2019-02-26 MX MX2020008816A patent/MX2020008816A/es unknown
- 2019-02-26 KR KR1020207025764A patent/KR20200126988A/ko not_active Application Discontinuation
- 2019-02-26 WO PCT/GB2019/050523 patent/WO2019162702A1/fr active Application Filing
- 2019-02-26 FI FIEP19710473.0T patent/FI3759088T3/fi active
- 2019-02-26 CA CA3090864A patent/CA3090864A1/fr active Pending
- 2019-02-26 JP JP2020544648A patent/JP7350759B2/ja active Active
- 2019-02-26 CN CN201980014798.6A patent/CN111819172B/zh active Active
- 2019-02-26 IL IL276624A patent/IL276624B2/en unknown
- 2019-02-26 PT PT197104730T patent/PT3759088T/pt unknown
- 2019-02-26 BR BR112020017341-0A patent/BR112020017341A2/pt unknown
- 2019-02-26 SI SI201930505T patent/SI3759088T1/sl unknown
- 2019-02-26 AU AU2019223333A patent/AU2019223333A1/en active Pending
- 2019-02-26 US US16/975,437 patent/US11352332B2/en active Active
- 2019-02-26 ES ES19710473T patent/ES2941529T3/es active Active
- 2019-02-26 HR HRP20230290TT patent/HRP20230290T1/hr unknown
- 2019-02-26 EP EP19710473.0A patent/EP3759088B8/fr active Active
- 2019-02-26 SG SG11202007136VA patent/SG11202007136VA/en unknown
- 2019-02-26 DK DK19710473.0T patent/DK3759088T3/da active
- 2019-02-26 LT LTEPPCT/GB2019/050523T patent/LT3759088T/lt unknown
-
2020
- 2020-07-09 ZA ZA2020/04220A patent/ZA202004220B/en unknown
- 2020-08-21 CL CL2020002157A patent/CL2020002157A1/es unknown
-
2022
- 2022-06-02 US US17/830,724 patent/US20220306589A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021514963A (ja) | 2021-06-17 |
| PT3759088T (pt) | 2023-04-10 |
| IL276624B2 (en) | 2023-10-01 |
| US20200399230A1 (en) | 2020-12-24 |
| JP7350759B2 (ja) | 2023-09-26 |
| KR20200126988A (ko) | 2020-11-09 |
| FI3759088T3 (fi) | 2023-04-05 |
| WO2019162702A1 (fr) | 2019-08-29 |
| IL276624A (en) | 2020-09-30 |
| CN111819172A (zh) | 2020-10-23 |
| HUE061751T2 (hu) | 2023-08-28 |
| US11352332B2 (en) | 2022-06-07 |
| ES2941529T3 (es) | 2023-05-23 |
| MX2020008816A (es) | 2020-09-28 |
| DK3759088T3 (en) | 2023-03-27 |
| EP3759088B8 (fr) | 2023-03-08 |
| HRP20230290T1 (hr) | 2023-05-26 |
| LT3759088T (lt) | 2023-05-10 |
| EP3759088B1 (fr) | 2023-01-25 |
| CL2020002157A1 (es) | 2020-12-18 |
| RU2020126542A (ru) | 2022-03-29 |
| ZA202004220B (en) | 2023-12-20 |
| SI3759088T1 (sl) | 2023-07-31 |
| BR112020017341A2 (pt) | 2020-12-15 |
| CN111819172B (zh) | 2024-02-06 |
| PL3759088T3 (pl) | 2023-07-03 |
| AU2019223333A1 (en) | 2020-08-27 |
| US20220306589A1 (en) | 2022-09-29 |
| IL276624B1 (en) | 2023-06-01 |
| SG11202007136VA (en) | 2020-08-28 |
| EP3759088A1 (fr) | 2021-01-06 |
| CA3090864A1 (fr) | 2019-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA52415A (fr) | Dérivés de triazine pour le traitement de maladies associées à des neurotrophines | |
| MA49767A (fr) | Conjugués de cytokine pour le traitement de maladies auto-immunes | |
| MA43746A (fr) | Dérivés de 2-cyanoisoindoline pour le traitement du cancer | |
| MA45539A (fr) | Dihydropyranopyrimidines pour le traitement d'infections virales | |
| MA51200A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
| MA51673A (fr) | Composés destinés au traitement de troubles dépendant de la kinase | |
| MA49144A (fr) | Polythérapies pour le traitement du cancer | |
| IL276398A (en) | Combined treatment for mastocytosis | |
| MA45481A (fr) | Utilisation d'exosomes pour le traitement de maladies | |
| MA55325A (fr) | Composés pour le traitement de maladies pd-l1 | |
| MA47719A (fr) | Esketamine pour le traitement de la dépression | |
| MA51203A (fr) | Combinaison d'un dérivé de 4-pyrimidinesulfamide avec un inhibiteur de sglt-2 pour le traitement de maladies liées à l'endothéline | |
| MA48637A (fr) | Polythérapies pour le traitement du cancer | |
| MA52218A (fr) | Traitement de cancers associés à trk | |
| MA43800A (fr) | Octréotide par voie orale pour le traitement de maladies | |
| MA46099A (fr) | Composés pour le traitement de maladies associées à un dysfonctionnement mitochondrial | |
| MA53614A (fr) | Protéine pour le traitement de maladies inflammatoires | |
| MA51738A (fr) | Composés pour le traitement de la douleur | |
| MA54077A (fr) | Polythérapie pour le traitement de maladies hématologiques | |
| MA53568A (fr) | Médicaments pour le traitement de maladies ophtalmiques | |
| MA52761A (fr) | Schéma posologique destiné au traitement de troubles liés à la pi3k | |
| IL281244A (en) | Therapeutic combination for the treatment of liver diseases | |
| MA53817A (fr) | Composés biphényl-sulfonamide destinés au traitement de maladies du collagène de type iv | |
| MA50495A (fr) | Composés bicycliques à fusion 5,6 et compositions pour le traitement de maladies parasitaires | |
| MA53636A (fr) | Agent de traitement de troubles dermatologiques |